La cadena de opciones muestra datos clave de las opciones de acciones de Evaxion Biotech a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Evaxion Biotech..

Evaxion Biotech (NASDAQ:EVAX) Bolsa, Cadena de Opciones

Evaxion Biotech

Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ACON

ACTG

ALUR

BTAI

CNTA

DALN

DWTX

EVAX

FFBC

HYZN

LITM

MLYS

NVNI

PBBK

SEPN

STBX

TRUG

TWLO

Twilio sube un 18,5% tras superar expectativas de ingresos. Explora los movimientos clave del mercado previo de hoy.

Acciones de Twilio (TWLO) se disparan más de un 18%; 20 acciones que se mueven en el premercado de EE.UU.

IDAI

INTZ

LIDR

LKCO

LUXH

MGIH

MLGO

MRBK

MTRX

NEUP

ONDS

QRHC

RVSN

SLDP

VIRX

WTBA

Descubre las acciones que lideran los movimientos en la apertura del mercado, incluyendo repuntes destacados y caídas sorprendentes.

Acciones de Evaxion Biotech (EVAX) suben alrededor del 62%; 20 acciones que se mueven en el premercado

Long Ideas

AREN

CSTM

GDYN

GEAR

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este viernes: CSTM, VIRX, EVAX, AREN y GDYN.

5 acciones en el foco este viernes: CSTM, VIRX, EVAX, AREN y GDYN

Evaxion Biotech A/S - American Depositary Share

Evaxion Biotech AS

The <a target="_blank" href="https://www.benzinga.com/topic/chips-act" rel="noreferrer noopener">U.S. Chips Program Office</a> will lose close to forty percent of its staff, marking a divergence in President&nbsp;Donald Trump&#8217;s strategy&nbsp;from that of Joe Biden.
The reduction includes around 20 employees who accepted a voluntary deferred resignation and left the U.S. government office last week, Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2025-03-03/us-chips-act-office-is-losing-two-fifths-of-staff-to-trump-purge?srnd=phx-technology&amp;sref=TBDibEcD" rel="noreferrer noopener">reported</a>, citing unnamed sources familiar with the matter. Reportedly, the Trump administration will terminate the office of another 40 who are considered probationary on Monday.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44084767/taiwan-semiconductor-weighs-100-billion-us-investment-as-chip-war-heats-up" rel="noreferrer noopener">Taiwan Semiconductor Weighs $100 Billion US Investment As Chip War Heats Up</a>
The 2022 program the Biden administration inked includes $39 billion in manufacturing grants to companies like&nbsp;Taiwan Semiconductor Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) and&nbsp;Intel Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>), plus $11 billion for research and development. It has prompted well over $400 billion in promised private investment.
Commerce Secretary&nbsp;Howard Lutnick suggested to Bloomberg that Trump tariffs have an edge over the erstwhile Chips Act.
He lauded how Trump convinced Taiwan Semiconductor to boost its U.S. investment by $100 billion to avoid tariffs instead of the erstwhile $65 billion Arizona fab investment in return for a 10% subsidy.
The Biden administration built an office of about 140 people to oversee the Chips Act manufacturing spending, in addition to staff responsible for R&amp;D funding.
The semiconductor supply chain disruption due to the 2020 pandemic and alleged national security threats from countries like China prompted countries like the U.S., Europe, and Japan to consolidate the domestic semiconductor base.
Therefore, they forged deals with the chipmakers to construct fabs in their countries to develop advanced semiconductor technology, notably artificial intelligence technology, to unlock value.
U.S. Big Tech giants have downsized by a <a target="_blank" href="https://www.benzinga.com/media/25/01/43352019/amazon-cuts-more-jobs-in-cost-saving-push-report" rel="noreferrer noopener">couple of thousands</a>, citing a pandemic-induced slowdown, an efficiency drive, and other factors.
In 2022, Amazon.Com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) let go of its workforce, affecting 27,000 positions. Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) fired 10,000 employees in 2023, losing 4%-5% of its workforce. In 2023, Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)&nbsp;Google&nbsp;slashed 12,000 jobs, affecting ~6% of its workforce. Since November 2022, Meta&nbsp;Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) laid off 21,000 employees or 25% of its workforce.&nbsp;
Also Read:
<ul>
<li><a href="https://www.benzinga.com/25/03/44087877/intel-stock-surges-as-nvidia-broadcom-test-18a-chips-amd-shows-interest" target="_blank" rel="noreferrer noopener">Intel Gains Traction With 18A Process As Nvidia, Broadcom Consider Manufacturing Contracts</a></li>
</ul>
Photo: Nazrul Iznan via Shuttestock

Government

Regulations

Tech

Media

AMZN

GOOG

GOOGL

INTC

MSFT

Taiwan Semiconductor, Intel Navigate Shift As Trump Looks To Slash Chips Act Workforce By 40%

Barclays analyst Benjamin Theurer maintains Coca-Cola Femsa SAB de (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KOF#NYSE">KOF</a>) with a Overweight and raises the price target from $99 to $105.

Price Target

Analyst Ratings

Barclays Maintains Overweight on Coca-Cola Femsa SAB de, Raises Price Target to $105

Barclays analyst David Anderson maintains Chart Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTLS#NYSE">GTLS</a>) with a Equal-Weight and raises the price target from $145 to $165.

GTLS

Barclays Maintains Equal-Weight on Chart Industries, Raises Price Target to $165

OLB Group Expands Fintech Offerings With New PayFac Service To Empower Small Business Growth

MASS

Trading Halt: Halt status updated at 7:55:00 AM ET: Quotation Resumption: News and Resumption Times

Barclays analyst Blayne Curtis maintains TXNM Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TXNM#NYSE">TXNM</a>) with a Overweight and raises the price target from $49 to $56.

TXNM

Barclays Maintains Overweight on TXNM Energy, Raises Price Target to $56

Additionally, divestiture streamlines operations, reducing headcount by approximately 33% and eliminating $20 million in annual operating losses.

Guidance

908 Devices Now Expects To Achieve Adjusted EBITDA Positivity By Q4 2025 And Cash Flow Positivity In 2026

This significant milestone demonstrates the U.S. government's long-standing support of quantum computing and networking
IonQ once again demonstrates its ability to deliver innovative quantum computing and networking systems to customers and partners worldwide

EXTR

Extreme Networks Becomes Official Wi-Fi And Analytics Provider For USL, Transforming Soccer Stadium Connectivity

Nordstrom, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JWN#NYSE">JWN</a>) will release its fourth-quarter financial results, after the <a href="https://www.benzinga.com/quote/JWN/earnings">closing bell, on Tuesday, March 4</a>.
Analysts expect the Seattle, Washington-based company to report quarterly earnings at 93 cents per share, down from 96 cents per share in the year-ago period. Ross Stores projects quarterly revenue of $4.33 billion, compared to $4.42 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Feb. 26, Nordstrom reported that its board of directors approved a quarterly dividend of 19 cents per share.
Nordstrom shares fell 0.2% to close at $24.24 on Monday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/JWN/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Evercore ISI Group analyst Michael Binetti maintained an In-Line rating and raised the price target from $22 to $24 on Jan. 13, 2025. This analyst has an accuracy rate of 63%.</li>
<li>UBS analyst Jay Sole upgraded the stock from Sell to Neutral and increased the price target from $14.5 to $24 on Jan. 10, 2025. This analyst has an accuracy rate of 70%.</li>
<li>B of A Securities analyst Lorraine Hutchinson maintained an Underperform rating and raised the price target from $20 to $22 on Nov. 27, 2024. This analyst has an accuracy rate of 67%.</li>
<li>Citigroup analyst Paul Lejuez maintained a Neutral rating and increased the price target from $22 to $23 on Nov. 19, 2024. This analyst has an accuracy rate of 65%.</li>
<li>JP Morgan analyst Matthew Boss maintained an Underweight rating and increased the price target from $19 to $20 on Aug. 28, 2024. This analyst has an accuracy rate of 67%.</li>
</ul>
Considering buying JWN stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="443" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/04055202/image-14-1024x443.png" alt="" class="wp-image-807808" style="width:615px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/04055202/image-14-1024x443.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/04055202/image-14-300x130.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/04055202/image-14-768x332.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/04055202/image-14.png 1462w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:<a href="https://www.benzinga.com/analyst-ratings/price-target/25/03/44083539/wall-streets-most-accurate-analysts-give-their-take-on-3-defensive-stocks-delivering-high-dividend-yields-3"> </a>
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/03/44083539/wall-streets-most-accurate-analysts-give-their-take-on-3-defensive-stocks-delivering-high-dividend-yields-3">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Defensive Stocks Delivering High-Dividend Yields</a></li>
</ul>

Earnings

Top Wall Street Forecasters Revamp Nordstrom Price Expectations Ahead Of Q4 Earnings

Barclays analyst Nicholas Campanella maintains Portland Gen Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/POR#NYSE">POR</a>) with a Equal-Weight and raises the price target from $42 to $47.

Barclays Maintains Equal-Weight on Portland Gen Electric, Raises Price Target to $47

Full year 2025 reported revenues are expected to be $54 million to $56 million, inclusive of approximately $1 million of desktop revenues in the first quarter, prior to divestiture.
Management expects further acceleration above 20% in 2026, driven by three defined catalysts: the need for equipment modernization, the launch of the next-gen MX908 mass spec, and the anticipated full-rate production award for the Department of Defense's AVCAD program.

908 Devices Expects 2025 Revenues From Cont Ops Of $53M - $55M, Representing 11% - 15% YoY Growth; Expects Further Acceleration Above 20% In 2026

Barclays analyst Nicholas Campanella maintains Talen Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLN#NASDAQ">TLN</a>) with a Overweight and lowers the price target from $293 to $282.

Barclays Maintains Overweight on Talen Energy, Lowers Price Target to $282

IONQ

IonQ Announced It Has Delivered And Commissioned Quantum Networking System Optimized For Research And Development To The U.S. Air Force Research Laboratory In Rome, New York

Barclays analyst Nicholas Campanella maintains Hawaiian Electric Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HE#NYSE">HE</a>) with a Equal-Weight and raises the price target from $10 to $11.

Barclays Maintains Equal-Weight on Hawaiian Electric Indus, Raises Price Target to $11

Evolution Petroleum Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPM#NYSE">EPM</a>) ("Evolution" or the "Company") today announced that it has entered into a definitive agreement to acquire non-operated oil and natural gas assets in New Mexico, Texas, and Louisiana (the "Acquisition"). The total purchase price for the Acquisition is $9.0 million, subject to customary closing adjustments. The Acquisition is expected to close by the end of Evolution's third quarter of fiscal 2025 with an effective date of February 1, 2025. The Company intends to finance the Acquisition through a combination of cash on hand and borrowings under its existing credit facility.
Kelly Loyd, President and Chief Executive Officer, commented: "This Acquisition marks our 7th such transaction in the last 6 years and is another step forward in strengthening our production base – aligns with our disciplined growth strategy by adding high-quality, low-decline production at an attractive valuation, estimated at ~2.8x NTM2 Adjusted EBITDA1 which doesn't include any incremental cash flows for upside opportunities. These assets complement our existing portfolio and enhance our ability to generate stable free cash flow, which supports our long-standing commitment to returning capital to shareholders. We see additional upside through reactivations of existing waterfloods and through operational efficiencies, which will further enhance long-term value."
The Acquisition expands Evolution's diverse asset portfolio with approximately 440 barrels of oil equivalent per day (BOEPD) of net production, consisting of a balanced commodity mix of 60% oil and 40% natural gas. The acquired assets are primarily low-decline, Proved Developed Producing (PDP) properties, characterized by a sub-7% annual base decline, ensuring stable cash flows and long-term value creation. The transaction is immediately accretive to all key metrics, reinforcing Evolution's ability to sustain and grow its shareholder returns. The portfolio consists of approximately 254 gross producing wells across all regions. The assets will be managed by a top-tier private operator, ensuring operational efficiency and the ability to maximize value.

Evolution Petroleum Acquires $9M Oil and Gas Assets, Expands Production in New Mexico, Texas, and Louisiana

908 Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASS#NASDAQ">MASS</a>) reported quarterly sales of $18.82 million which beat the analyst consensus estimate of $16.39 million by 14.85 percent. This is a 31.14 percent increase over sales of $14.35 million the same period last year.

Earnings Beats

908 Devices Q4 Sales $18.82M Beat $16.39M Estimate

This approval marks a significant milestone in emissions management, empowering operators to integrate AOGI into their emissions monitoring programs to detect and locate fugitive methane emissions with unmatched efficiency and precision.

ChampionX's Aerial Optical Gas Imaging (AOGI) Platform Earns EPA Approval

General

Redwire Bags Study Contract By The European Space Agency (ESA) To Conceptualize A spacecraft Platform For Mars

Barclays analyst Nicholas Campanella maintains Ameren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEE#NYSE">AEE</a>) with a Equal-Weight and raises the price target from $95 to $102.

Barclays Maintains Equal-Weight on Ameren, Raises Price Target to $102

Wellgistics Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGRX#NASDAQ">WGRX</a>, the ", Company", ))), a holding company for various existing and planned strategic businesses centered around healthcare technology and pharmaceutical services, today announced that its wholly owned subsidiary, Wellgistics LLC, is collaborating with Protega Pharmaceuticals Inc. ("Protega"). Protega is the innovative specialty pharmaceutical company that launched ROXYBOND&#x2122; (oxycodone hydrochloride), the first and only FDA-approved abuse-deterrent immediate-release (IR) opioid pain medication in the U.S. The collaboration is meant to support pharmacist education on abuse-deterrent pain management options and regulatory compliance as well as increase patient access to ROXYBOND&#x2122; for appropriately prescribed patients.
Wellgistics LLC is a pharmaceutical wholesaler and National Association of Boards of Pharmacy ("NABP") authorized distributor that serves over 5,400 independent pharmacies across all 50 states. The relationship will support education to these pharmacies and help provide distribution of ROXYBOND&#x2122; to appropriately prescribed patients, particularly in underserved and rural areas where Wellgistics LLC's independent pharmacy clients play a critical role in patient care.

WGRX

Wellgistics Partners with Protega to Expand Access to Abuse-Deterrent Opioid Pain Medication, Support Pharmacist Education, Distribute ROXYBOND to Independent Pharmacies Nationwide

Press Releases

Evaxion announces plan to implement ADS ratio change

Evaxion announces extension to January 14, 2025, of plan to implement ADS ratio change

Evaxion announces completion of ADS ratio change

Evaxion completes dosing in phase 2 trial with personalized cancer vaccine EVX-01

Evaxion granted 180-day compliance extension by Nasdaq as it restores equity above minimum requirement

Evaxion announces pricing of $10.8 million public offering

Evaxion announces closing of $10.8 million public offering

Peraso Inc. (NASDAQ: PRSO) Rides Military AI Boom as Defense Spending Surges – More Stocks Inside

Nasdaq confirms Evaxion is fully compliant, withdraws delisting determination

Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package

Comments

Evaxion Biotech

Evaxion Biotech (EVAX) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL